The stock of Eli Lilly and Company (LLY) has declined 1.7% already this week, losing almost $14 billion of its market value. Earlier this month, the FDA removed Lilly’s popular GLP-1 drug tirzepatide from its shortage list after confirming with Lilly that it can meet the present and future demand with its manufacturing expansion. Lilly markets tirzepatide as Mounjaro for type II diabetes and Zepbound for obesity. Due to increased demand, tirzepatide was added to the FDA’s shortage list in 2022.In the United ...